New publications in health economics and genomics 11th August 2020

Two publications from the last two weeks:

  • Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer | link
  • PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 21st July 2020

One publication this week:

  • Next generation use in Oncology, a better information on patients’ genetic profiles improved access to matched treatments and earlier NGS use show better outcomes | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 14th July 2020

Three publications this week:

  • PARC report: health outcomes and value of personalized medicine interventions: impact on patient care | link
  • The Daunting Economics of Therapeutic Genome Editing | link
  • Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 7th July 2020

No publications last week, but five (well, kind of) this week:

  • Costs of In-House Genomic Profiling and Implications for Economic Evaluation: A Case Example of Non-Small Cell Lung Cancer (NSCLC) | link
  • Multi-gene Assays: Effect on Chemotherapy Use, Toxicity and Cost in Estrogen Receptor-Positive Early Stage Breast Cancer | link
  • Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer? | link
  • Economic Value of Exome Sequencing for Suspected Monogenic Disorders [letter] | link
  • Response to Ferket Et Al [response to letter] | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 23rd June 2020

No publications last week, but a glut of new publications related to multi-gene panels this week, four in total:

  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention | link
  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention | link
  • Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer | link
  • Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

An odd paper: Next-Generation Sequencing for Diagnosing Periprosthetic Joint Infection

One of the new publications that appeared in my searches this week was this paper on “Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis”, published in The Journal of Arthroplasty. I wrote about it on this Twitter thread, but I just wanted to expand on a couple of points here.

Continue reading

New publications in health economics and genomics 9th June 2020

I’ve been sharing weekly updates of new publications in health economics and genomics on social media for a few weeks, but thought it would be useful if I also presented these updates in weekly blog posts.

There are 2 new publications this week:

As I’m putting these in a blog post for the first time, here are the latest publications from the past four weeks too: Continue reading

New special theme section in Value in Health on Precision Medicine

In 2018, I contributed to the publication of a special theme section in Value in Health on assessing the value of clinical genomic testing. You can read a blog post about this publication here, and access the special issue here. My contribution to this was as a member of the Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS), formerly known as the Population Genomics Health Economists Working Group.

I’m pleased to say that we have just published a second theme section in the same journal, this time focused on evaluation methods for moving precision medicine into practice and policy. This theme section features five papers from the GEECS team and one paper by the ISPOR Special Interest Group on Precision Medicine and Advanced Therapies. As before, the work was chaired by Kathryn A. Phillips, PhD.

Continue reading

Are the costs of genome sequencing underestimated?

Four years ago I blogged on how “The $1000 genome is a myth”. I think the first paragraph from that blog post is as relevant today as it was in 2015:

Barely a day goes by without a news story or social media post proclaiming that the $1000 genome now exists, and is ushering in a healthcare revolution. Every day, somebody, somewhere in the world, posts these graphs on Twitter. There’s even a Wikipedia page devoted to this topic. It’s a persistent news headline and, frustratingly, it’s currently wrong.

Since 2015, the health economic evidence base for genome sequencing has gradually expanded, and several cost estimates are now available, but overall I think we still lack the sort of rigorously conducted microcosting studies that can usefully inform resource allocation decisions regarding genomic testing.

Hopefully this paper that we published in Genetics in Medicine a couple of weeks’ ago can make such a contribution.

Continue reading

Blog posts welcome!

When I started this blog in 2014 I wanted to provide a forum for the discussion of issues surrounding the health economic analysis of genomic technologies. I knew that I would start off by writing most of the blog posts, but my plan in the medium-term was to invite researchers from all backgrounds to contribute posts. However, this was not something I ever really got around to publicising. Consequently there has only been one guest post since this blog began.

I have less time to write for the blog now, so this seems like a good opportunity to put the call out for more guest posts. If you would like to contribute a post on any topic related to health economics and genomics, please get in touch. You can do this via the contact form, or via a DM on Twitter, or via my email address. There are no restrictions on the topic of posts: these could be paper reviews, comments on current issues in the field, editorial type posts, methods discussions or even debate-type posts. If you have something to say on health economics and genomics that requires more space than the 280 characters offered by Twitter, but isn’t quite right for a formal peer-reviewed paper, then this could be the format for you. I do not intend/want to edit any posts other than to do some light touch editing to fix typos etc.: there is no blog ‘voice’, and all opinions are welcome.

If you are interested in contributing, please get in touch!